NOVMETAPHARMA

Main Pipeline

For Your Healthy Life, NovMetaPharma

Diabetes Medication (NovDB2)

Pipeline
NovDB2
Program Target
Type 2 Diabetes
Patient Numbers
629 Million
Development Stage
Phase II
NovMetaPharma develops NovDB2, an insulin sensitivity improving agent of first-in-class new substance.
Confirmation of NovDB2’s
Insulin Sensitivity Improvement Function

Currently, most of the type 2 diabetes medication market is insulin injection or simple blood sugar control drugs, which do not have the effect of improving insulin sensitivity, the underlying cause of diabetes. In the case of the TZD series, the only commercially available insulin sensitivity improving agent, not only risks of cardiovascular disease and bladder cancer but also side effects of weight gain have been identified.

On the other hand, NovDB2 has been confirmed to improve insulin sensitivity in a clinical trial by the US FDA. Also, the superior safety of NovDB2 has been verified in clinical trials such as chronic toxicity and reproductive toxicity conducted in the same clinical trial. On top of such insulin sensitivity improvement function and safety, NovDB2 has proven its unrivaled weight control effect as well.

As a groundbreaking insulin sensitivity improving agent that will change the game in the diabetes medication market, NovDB2 will be presented as a clear solution to the global demand for fundamental diabetes medication.

01

Insulin resistance improvement effect

The trend of improving insulin sensitivity was confirmed in indicators related to type 2 diabetes treatment such as HbA1c, fasting blood sugar, and insulin and glucose tolerance by the US FDA clinical phase 2 (including a and b).

02

Safety

Safety such as chronic toxicity and reproductive toxicity has been verified through several global clinical and non-clinical trials.

03

Weight loss

Significant G114 reduction in weight has been confirmed through the US FDA clinical phase 2 (including a and b).

NovDB2 Development Status

01

Clinical Development Status
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022

Clinical phase 2c

License Out (E)

US clinical phase 3

02

Patent Application and Registration Status
Patents IP Protection
Substance patent (US)
Application
2019
Registration
2020
Patent expiration (expected) year
2039
Diabetes dosage patent (KR)
Application
2017
Registration
2020
Patent expiration (expected) year
2037
Diabetes dosage patent (US)
Application
2020
Patent expiration (expected) year
(2040)
Compound medication patent (KR)
Application
2018
Registration
2020
Patent expiration (expected) year
2038
Compound medication patent (US)
Application
2020
Patent expiration (expected) year
(2038)
Compound medication patent (EU)
Application
2020
Patent expiration (expected) year
(2038)
Compound medication patent (JP)
Application
2020
Patent expiration (expected) year
(2038)
Compound medication patent (CN)
Application
2020
Patent expiration (expected) year
(2038)
Compound medication patent (HK)
Application
2020
Patent expiration (expected) year
(2038)